-
Je něco špatně v tomto záznamu ?
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions
Marketa Hermanova, Jan Trna, Rudolf Nenutil, Petr Dite, Zdenek Kala
Jazyk angličtina Země Velká Británie
Grantová podpora
NR9295
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
- MeSH
- adenokarcinom metabolismus patologie MeSH
- cyklooxygenasa 2 metabolismus MeSH
- dospělí MeSH
- duktální karcinom slinivky břišní metabolismus patologie MeSH
- financování organizované MeSH
- imunoenzymatické techniky MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorový supresorový protein p53 metabolismus MeSH
- nádory slinivky břišní metabolismus patologie MeSH
- prekancerózy metabolismus patologie MeSH
- progrese nemoci MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vývody pankreatu metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
OBJECTIVES: Cyclooxygenase-2 (COX-2) and tumor suppressor p53 are molecules that are linked to the oncogenesis of pancreatic cancer. COX-2 represents a key modulatory molecule in inflammation and carcinogenesis, and is known to be implicated in the positive regulation of growth and tumorigenesis. Abnormal expression of p53 is common in many human neoplasms including pancreatic cancer. Recent studies demonstrated functional interactions between p53 and COX-2. The p53-dependent upregulation of COX-2 was proposed to be another mechanism by which p53 could abate its own growth-inhibitory and apoptotic effects. METHODS: In this study, we immunohistochemically analyzed the expression of COX-2 and p53 in 95 pancreatic resection specimens [adenocarcinomas, 95 lesions; pancreatic intraepithelial neoplasias (PanINs), 155; normal ducts, 70]. RESULTS: The expression of COX-2 increased progressively with the grade of ductal lesions (P<0.00001). A statistically significant difference of COX-2 expression between normal ducts and low-grade PanINs was revealed (P=0.0042). COX-2 overexpression was demonstrated in 82 PanINs (52.9%), and in 76 adenocarcinomas (80%). No significant correlation between the grade of adenocarcinoma and COX-2 expression was revealed (P=0.2). The expression of p53 again increased progressively with the grade of lesions (P<0.00001) with a significant increase in high-grade PanINs. A correlation between COX-2 and p53 expression levels in carcinomas was revealed (P=0.0002), and an accumulation of p53 was associated with COX-2 overexpression in premalignant and malignant ductal lesions. CONCLUSION: These findings confirmed the generally accepted pancreatic cancer progression model, and supported the concept of the interactive role of COX-2 and p53 in pancreatic cancer carcinogenesis, which offers opportunities for targeted therapy and chemoprevention of pancreatic cancer using COX-2 inhibitors.
Department of Gastroenterology Masaryk University and University Hospital Brno Brno Czech Republic
Department of Pathology Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Pathology Masaryk University and University Hospital Brno Brno Czech Republic
Department of Surgery Masaryk University and University Hospital Brno Brno Czech Republic
- 000
- 02602naa 2200493 a 4500
- 001
- bmc11005031
- 003
- CZ-PrNML
- 005
- 20140721135633.0
- 008
- 110311s2008 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Hermanová, Markéta $7 xx0073982 $u Department of Pathology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 245 10
- $a Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions / $c Marketa Hermanova, Jan Trna, Rudolf Nenutil, Petr Dite, Zdenek Kala
- 314 __
- $a Department of Pathology, Masaryk University and University Hospital Brno, Brno, Czech Republic. marherman@post.cz
- 520 9_
- $a OBJECTIVES: Cyclooxygenase-2 (COX-2) and tumor suppressor p53 are molecules that are linked to the oncogenesis of pancreatic cancer. COX-2 represents a key modulatory molecule in inflammation and carcinogenesis, and is known to be implicated in the positive regulation of growth and tumorigenesis. Abnormal expression of p53 is common in many human neoplasms including pancreatic cancer. Recent studies demonstrated functional interactions between p53 and COX-2. The p53-dependent upregulation of COX-2 was proposed to be another mechanism by which p53 could abate its own growth-inhibitory and apoptotic effects. METHODS: In this study, we immunohistochemically analyzed the expression of COX-2 and p53 in 95 pancreatic resection specimens [adenocarcinomas, 95 lesions; pancreatic intraepithelial neoplasias (PanINs), 155; normal ducts, 70]. RESULTS: The expression of COX-2 increased progressively with the grade of ductal lesions (P<0.00001). A statistically significant difference of COX-2 expression between normal ducts and low-grade PanINs was revealed (P=0.0042). COX-2 overexpression was demonstrated in 82 PanINs (52.9%), and in 76 adenocarcinomas (80%). No significant correlation between the grade of adenocarcinoma and COX-2 expression was revealed (P=0.2). The expression of p53 again increased progressively with the grade of lesions (P<0.00001) with a significant increase in high-grade PanINs. A correlation between COX-2 and p53 expression levels in carcinomas was revealed (P=0.0002), and an accumulation of p53 was associated with COX-2 overexpression in premalignant and malignant ductal lesions. CONCLUSION: These findings confirmed the generally accepted pancreatic cancer progression model, and supported the concept of the interactive role of COX-2 and p53 in pancreatic cancer carcinogenesis, which offers opportunities for targeted therapy and chemoprevention of pancreatic cancer using COX-2 inhibitors.
- 650 _2
- $a adenokarcinom $x metabolismus $x patologie $7 D000230
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a duktální karcinom slinivky břišní $x metabolismus $x patologie $7 D021441
- 650 _2
- $a cyklooxygenasa 2 $x metabolismus $7 D051546
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoenzymatické techniky $7 D007124
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a vývody pankreatu $x metabolismus $7 D010183
- 650 _2
- $a nádory slinivky břišní $x metabolismus $x patologie $7 D010190
- 650 _2
- $a prekancerózy $x metabolismus $x patologie $7 D011230
- 650 _2
- $a nádorový supresorový protein p53 $x metabolismus $7 D016159
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Trna, Jan $7 xx0143351 $u Department of Gastroenterology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Nenutil, Rudolf $7 xx0057842 $u Department of Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Dítě, Petr, $d 1941- $7 jn20000400604 $u Department of Gastroenterology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Kala, Zdeněk, $d 1960- $7 xx0003702 $u Department of Surgery, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 773 0_
- $t European Journal of Gastroenterology & Hepatology $w MED00001618 $g Roč. 20, č. 8 (2008), s. 732-739 $x 0954-691X
- 910 __
- $a ABA008 $b x $y 1 $z 0
- 990 __
- $a 20110414094055 $b ABA008
- 991 __
- $a 20140721135940 $b ABA008
- 999 __
- $a ok $b bmc $g 832895 $s 697073
- BAS __
- $a 3
- BMC __
- $a 2008 $b 20 $c 8 $d 732-739 $i 0954-691X $m European journal of gastroenterology & hepatology $n Eur J Gastroenterol Hepatol $x MED00001618
- GRA __
- $a NR9295 $p MZ0
- LZP __
- $a 2011-4B/vtme
